Home
A Different Class of ADT
Control CV Risk
Economic Burden of CVD Events
Disease-Related Symptoms
Delay Disease Progression
Patient Satisfaction
Support & Resources
Dosing & Administration
Firmagon Licence
Prescribing Information
DEGARELIX FERRING can delay disease progression1,2,5
Time is incredibly valuable to you and your patients. See how DEGARELIX FERRING can give you more.
Learn More...
DEGARELIX FERRING increases PSA progression-free survival at 12 months vs. LHRH agonists1,5
DEGARELIX FERRING delays PSA failure or death by 7 months (secondary endpoint)2*,**,†
- Delays PSA failure or death by 7 months in high-risk patients** and can maintain this response long-term2
- Increases PSA progression-free survival at 12 months,1 with response maintained to 5 years in significantly more high-risk patients vs. LHRH agonists2
Adapted from Boccon-Gibod L, et al. 2012
*In a long-term extension of a Phase 3 trial. Delay defined as time taken for 25% of patients considered to be at high-risk (with a baseline PSA ≥ 20 ng/ml) to experience PSA failure or death (TTP 25%).
TTP25% was significantly longer with DEGARELIX FERRING than leuprorelin (514 vs. 303 days, p=0.001).
**As calculated using the Weibull estimate.
† The primary endpoint of the trial was suppression of testosterone to ≤ 0.5 ng/ml at all monthly measurements from day 28 to day 364
DEGARELIX FERRING provides effective treatment for high-risk prostate cancer patients1-3
*High risk defined as patients with baseline PSA ≥20 ng/ml.1,2
